| P2093 | author name string | Pei-Quan Zhao | |
| | Huang Zhu | |
| | Yi-Qian Hu | |
| | Li-Quan Zhao | |
| P2860 | cites work | Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema | Q24240165 |
| | Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses | Q27860840 |
| | Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy | Q33249402 |
| | Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). | Q33265701 |
| | A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema | Q33294185 |
| | Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema | Q33431723 |
| | Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. | Q33507333 |
| | Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy | Q33529769 |
| | Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage | Q34498424 |
| | Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology | Q37301735 |
| | Bevacizumab (Avastin) for the treatment of ocular disease | Q37473784 |
| | Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). | Q41811970 |
| | Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage? | Q45955521 |
| | Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. | Q45974150 |
| | Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). | Q46125936 |
| | Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up | Q46135612 |
| | Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series | Q46304408 |
| | Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy | Q46434222 |
| | Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy | Q46493637 |
| | Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy | Q46545305 |
| | Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study | Q46731511 |
| | Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy | Q46927800 |
| | Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial | Q46965253 |
| | Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. | Q51768441 |
| | Overcoming the limitations of current meta-analysis of randomised controlled trials. | Q52900034 |
| | Penetration of bevacizumab through the retina after intravitreal injection in the monkey. | Q53479816 |
| | Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). | Q53811346 |
| | Pharmacokinetics of intravitreal bevacizumab (Avastin) | Q80235081 |
| | Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy | Q81343161 |
| | Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial | Q84449276 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| | monoclonal antibody | Q422248 |
| | blood proteins | Q425056 |
| | angiogenesis inhibitor | Q574834 |
| | diabetic retinopathy | Q631361 |
| | meta-analysis | Q815382 |
| | systematic review | Q1504425 |
| | globulins | Q321710 |
| | postoperative complications | Q18478450 |
| | surgical blood loss | Q65619893 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1216-1222 | |
| P577 | publication date | 2011-01-27 | |
| | 2011-09-01 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy | |
| P478 | volume | 95 | |